Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

LEUVEN, Belgium, September 11 /PRNewswire-FirstCall/ --

- ThromboGenics' Significant Achievements Over the Last Year are Recognised in Nominations

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009. These nominations recognise the transformational year that ThromboGenics has had, and the progress it has made toward becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines.

The Biotech Company of the Year award recognises the progress and achievement a biotech company has made within the last twelve months. During the period, ThromboGenics has started the pivotal transatlantic Phase III programme with microplasmin for back of the eye disease, signed a EUR500 million partnership deal with Roche for its novel anti-cancer antibody TB-403, and moved its novel anti-coagulant TB-402 into Phase II trials. TB-402 is another potential partnership opportunity. There are four other companies nominated in this category.

The Licensing Deal of the Year award acknowledges the achievement of a Company in signing a licensing deal that has both monetary and strategic benefits to all parties. ThromboGenics signed a major partnership deal with Roche for TB-403 under which the Company and co-development partner BioInvent received an upfront payment of EUR50 million, an additional EUR450 million in potential milestones, and double digit royalties on future product sales. There are four other licensing deals nominated in this category.

The Scrip Awards is one of the biotechnology and pharmaceutical industry's most prestigious and highly contested awards event. The event is in its fif
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2014)... Boehringer Laboratories Inc., with a forty ... announce the successful broadcast of a live surgery by ... MD, FACS, FAMBS, and Maher El Chaar, MD, FACS, ... , This sleeve gastrectomy surgery was performed and ... four hundred surgeons from around the world during the ...
(Date:9/12/2014)... , Sept. 12, 2014   Arthur Kay ... bio-bean, has won the Postcode Lottery Green Challenge 2014. ... Kay euro 500,000 ($680,000 USD) at the final in ... business plan. Kay,s company uses a ... biofuel products, namely biodiesel and biomass pellets, used for ...
(Date:9/12/2014)... 2014 Research and Markets has ... Photoresist Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... industry . The report provides a basic ... industry chain structure. The dry film photoresist market analysis ...
(Date:9/12/2014)... LONDON , September 12, 2014 ... 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the ... at 1,997.45, up 0.09%. The gains were broad based as ... The S&P 500 Health Care Sector Index ended the day ... in the last one month. Investor-Edge has initiated coverage on ...
Breaking Biology Technology:Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 3Global Dry Film Photoresist Industry Report 2014 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... Australia, January 23, 2012 Ansell Limited ... it has entered into a multi-year agreement with Koreca ... a leading hand protection specialist in Korea. ... Koreca Industries its exclusive distributor of Industrial and New ...
... 23, 2012   BioLife Solutions , Inc. (OTCBB: BLFS), ... hypothermic storage and cryopreservation freeze media ... additional key opinion leaders in the biobanking , ... markets have joined the Company,s Scientific Advisory Board ...
... Scientists at deCODE Genetics and academic ... report the discovery of variants in the human genome ... risk of thyroid cancer.The paper ,Discovery of common variants ... is published today in the online edition of ...
Cached Biology Technology:BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 2BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 3BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 4BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 5deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer 2
(Date:9/16/2014)... PALM BEACH GARDENS, Fla. , Sept. 16, ... provider of biometric identity management solutions, announced today ... handheld solution designed to authenticate the identity of ... The Android-based Verifier Sentry rapidly reads ... the credential holder,s ID by matching the biometric ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... single group of microorganisms may be responsible for much ... with implications for the global carbon cycle and climate ... required by most life on this planet, it is ... because it is so large and complex. For humans, ... brain and nervous systems, as well as DNA synthesis ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2Researchers discover new producer of crucial vitamin 2
... Researchers at Ume Plant Science Center in Sweden discovered, in ... sugar beets that blocks flowering. Only with the cold of ... to blossom in its second year. The discovery of this ... beets bloom. The new findings were recently published in the ...
... consumed, researchers have learned that up to 90 percent ... the drugs can leave the body almost intact through ... areas, excreted antibiotics can then enter stream and river ... animal feeding operations, fish hatcheries, and nonpoint sources such ...
... Rensselaer Polytechnic Institute assistant professor of chemical and biological ... engineers developing exciting and novel new techniques to treat ... disease, Parkinson,s disease, traumatic brain injury, and brain cancer. ... Goldhirsh Foundation and now has garnered the support of ...
Cached Biology News:New discovery about how flowering time of plants can be controlled 2Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution 2Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution 3Delivering drugs to the brain: New research into targeted treatment of Alzheimer's 2Delivering drugs to the brain: New research into targeted treatment of Alzheimer's 3
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
Biology Products: